Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96

The IBD SmartSelect Composite Rating for Supernus Pharmaceuticals (SUPN) increased from 94 to 96 Thursday.


The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Supernus Pharmaceuticals is now out of buy range after breaking out from a 25.30 buy point in a cup with handle. Avoid buying extended stocks as it’s more likely to retract. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.


Looking For The Best Stocks To Buy And Watch? Try These Exclusive Lists


The stock has a 91 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 91% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

In Q3, the company reported 37% earnings growth. Top line growth increased 52%, up from 21% in the prior quarter. That marks three quarters of rising growth. The company’s next quarterly report is expected on or around Feb. 25.

Supernus Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Horizon Pharma (HZNP) is the top-ranked stock within the group. For more industry news, check out “Biotech And Pharma Industry And Stock News“.


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button